IL6 and neoplasm: Previous research findings indicated that combined targeting of IL-6/JAK/STAT pathway and PD-L1 resulted in restricted tumor growth in in vivo models [36,37], while in others, STAT3 targeting increased the efficacy of anti-PD1 mAb [38].